Novavax, Inc. [NASDAQ: NVAX] plunged by -$0.18 during the normal trading session on while it closed the day at $10.07.
Novavax, Inc. stock has also loss -0.49% of its value over the past 7 days. However, NVAX stock has declined by -21.39% in the 3 months of the year. Over the past six months meanwhile, it has gained 132.56% and gained 109.79% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for NVAX stock reached $1.61 billion, with 160.09 million shares outstanding and 153.03 million shares in the current float. Compared to the average trading volume of 6.55M shares, NVAX reached a trading volume of 4471699 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Novavax, Inc. [NVAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVAX shares is $17.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVAX stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Novavax, Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on July 30, 2024. The new note on the price target was released on May 10, 2024, representing the official price target for Novavax, Inc. stock. Previously, the target price had yet another raise from $4 to $12, while BofA Securities kept a Neutral rating on NVAX stock.
The Average True Range (ATR) for Novavax, Inc. is set at 0.85, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 1.63.
NVAX stock trade performance evaluation
Novavax, Inc. [NVAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.49. With this latest performance, NVAX shares dropped by -20.27% in over the last four-week period, additionally plugging by 132.56% over the last 6 months – not to mention a rise of 58.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 37.33, with the RSI for the last a single of trading hit 34.35, and the three-weeks RSI is set at 40.25 for Novavax, Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 12.09, while it was recorded at 10.00 for the last single week of trading, and 9.72 for the last 200 days.
Novavax, Inc. [NVAX]: An insightful look at the core fundamentals
Novavax, Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.03 and a Current Ratio set at 1.04.
Earnings per share (EPS) analysis for Novavax, Inc. [NVAX] stock
With the latest financial reports released by the company, Novavax, Inc. posted -1.26/share EPS, while the average EPS was predicted by analysts to be reported at -1.83/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.57. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax, Inc. go to 37.90%.
Novavax, Inc. [NVAX]: Institutional Ownership
There are presently around $54.19%, or 56.67%% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: VANGUARD GROUP INC with ownership of 14.08 million shares, which is approximately 10.0599%. BLACKROCK INC., holding 11.85 million shares of the stock with an approximate value of $$149.98 million in NVAX stocks shares; and BLACKROCK INC., currently with $$122.32 million in NVAX stock with ownership which is approximately 6.9056%.
